Bladder Cancer and Upper Tract Urothelial Carcinoma – Geographic Focus: China – Bladder Cancer and Upper Tract Urothelial Carcinoma | China In-Depth (China)
Bladder cancer is the eighth most diagnosed kind of cancer in China. The bladder cancer therapy market will experience rapid growth over the forecast period, fueled by one of the most robust drug-development pipelines in oncology. Notably, the biggest market driver will be the anticipated approval of multiple immune checkpoint inhibitors from both multinational corporations and domestic companies; these agents will transform the treatment paradigm. Additionally, biomarker-driven therapies—Janssen’s Balversa for patients harboring FGFR mutations—are becoming increasingly attractive, and many new therapies, such as Padcev, MRG002, APL102, and sasanlimab, are expected to be approved during the forecast period, resulting in the availability of more-effective treatments for urothelial carcinoma. In this report, we explore how unmet need, pricing, coverage, and regulatory reforms in the A&R landscape of China will impact the success of current and future players in this highly lucrative market.
Questions answered
- How large is China’s drug-treatable bladder cancer population, and how will drug-treatment rates change during the forecast period?
- Which are the most commercially relevant drugs in China’s bladder cancer market and why?
- What are interviewed experts’ insights into current treatment options?
- What are the key unmet needs in the treatment of bladder cancer in China?
- What are the key market access considerations, and how will they impact the uptake of emerging therapies for bladder cancer in China?
- What are the key drivers and constraints in this market, and how will the market evolve over the forecast period?
Content highlights
Geography: China
Primary research: Country-specific qualitative and quantitative insights based on 5 thought-leader interviews and surveys of 67 medical oncologists and 33 urologists.
Epidemiology: Diagnosed incidence of bladder cancer and upper tract urothelial carcinoma (UTUC) in urban versus rural China; clinically and market-relevant drug-treatable populations.
Forecast: 10-year, annualized, drug-level sales and patient share of key bladder cancer therapies through 2032, based on primary and secondary market research to formulate bottom-up assumptions.
Emerging therapies: Phase III/PR: 10+ drugs; Phase II: 10+ drugs; coverage of select Phase I and Phase I/II products.
Product description
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
